A Study to Evaluate the Use of Nitazoxanide to Treat Cryptosporidiosis
Cryptosporidiosis, HIV Infections
About this trial
This is an interventional treatment trial for Cryptosporidiosis focused on measuring Cryptosporidiosis, Diarrhea, Acquired Immunodeficiency Syndrome, nitazoxanide, Antiparasitic Agents
Eligibility Criteria
Inclusion Criteria Patients may be eligible for this study if they: Are 3 to 65 years old (need consent of parent or guardian if under 18). Have AIDS. Have a CD4 count less than or equal to 200 cells/mm3. (Note: Patients with a CD4 count greater than 200 cells/mm3 but who have had cryptosporidiosis for at least 4 weeks may be eligible for this study.) Test positive for the parasite Cryptosporidium and have severe diarrhea (at least 4 bowel movements per day) for at least 2 weeks. Have received treatment for cryptosporidiosis but have become reinfected after treatment. Agree to practice abstinence or use effective methods of birth control (such as a condom) before and during the study. Exclusion Criteria Patients will not be eligible for this study if they: Are pregnant. Are infected with certain other parasites. Have a history of certain intestinal diseases. Have received certain medications.
Sites / Locations
- Romark Laboratories LC